Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.52 |
| ▸ | CDC7 | O00311 | 2/20 | 0.45 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.43 |
| ▸ | RAB9A | P51151 | 3/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.39 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14740334 | 0.91 | CDC7 (0.46) | CYP1A2CYP2C9CYP2C19CDC7DBF4 | |
| SCHEMBL14739556 | 0.88 | CYP1A2 (0.53) | CYP1A2CYP2C9CYP2C19CDC7DBF4 | |
| SCHEMBL14739524 | 0.85 | GAA (0.52) | CYP1A2CYP2C9CYP2C19CDC7DBF4 | |
| SCHEMBL14740062 | 0.85 | CYP1A2 (0.65) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 | |
| SCHEMBL14739455 | 0.83 | JAK2 (0.40) | SMN1; SMN2NPC1RAB9APOLBTSHR | |
| SCHEMBL14739693 | 0.81 | ALDH1A1 (0.48) | CYP1A2CYP2C19NPC1RAB9ADPP4 | |
| SCHEMBL14739475 | 0.80 | PDE4A (0.51) | CYP1A2CYP2C9CYP2C19CDC7DBF4 | |
| SCHEMBL14739289 | 0.79 | KDM4E (0.63) | CYP1A2CYP2C9CYP2C19CDC7DBF4 | |
| SCHEMBL20579735 | 0.78 | CYP1A2 (0.72) | CYP1A2CYP2C9CYP2C19CDC7DBF4 | |
| SCHEMBL30765413 | 0.76 | CYP1A2 (0.43) | CYP1A2CYP2C9CYP2C19SMN1; SMN2NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9593109-B2 | Bicyclic agonists of GPR131 and uses thereof | CYMABAY THERAPEUTICS, INC. (US) | 2017-03-14 | — | — | US | disclosed |
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | METABOLEX, INC. | 2013-03-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130059845-A1 | BICYCLIC AGONISTS OF GPR131 AND USES THEREOF | GPR119, GPR88, GPR3 | CYP1A2 1164/4885CYP2C9 3119/4885CYP2C19 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.